You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

brigatinib

Showing 1 - 25 of 25
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Volunteers Trial in Tempe (Brigatinib)

Not yet recruiting
  • Healthy Volunteers
  • Brigatinib
  • Tempe, Arizona
    Celerion, Inc.
Nov 10, 2023

Information Available in Chinese Non-Small-cell Lung Cancer

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Brigatinib
  • Shanghai, Shanghai, China
    Department of Oncology, Shanghai pulmonary hospital
Feb 1, 2023

d To Treat People With Non-Small Cell Lung Cancer

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Brigatinib
  • Tokyo, Japan
    Takeda Selected Site
Oct 13, 2022

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Brigatinib
  • Paris, France
  • +1 more
Sep 27, 2022

NSCLC Trial in United States (brigatinib)

Terminated
Has Results
  • Non-Small Cell Lung Cancer
  • brigatinib
  • Denver, Colorado
  • +3 more
Jan 10, 2023

Non Small Cell Lung Cancer Trial in Goyang-si (Brigatinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Brigatinib
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

NSCLC Trial in Seoul (Brigatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Brigatinib
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Apr 29, 2022

NSCLC, Stage III, ALK-rearrangement Trial in Worldwide (Brigatinib, Durvalumab)

Not yet recruiting
  • NSCLC, Stage III
  • ALK-rearrangement
  • Angers, France
  • +19 more
Feb 8, 2023

Brain Metastases, Lung Cancer Trial in Duarte, Aurora, Rochester (Brigatinib)

Active, not recruiting
  • Brain Metastases
  • Lung Cancer
  • Brigatinib
  • Duarte, California
  • +2 more
Feb 8, 2022

NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

Recruiting
  • NSCLC
  • Brigatinib
  • Tyrosine kinase inhibitor
  • Berlin, Germany
  • +25 more
Nov 10, 2022

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Brigatinib
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Bevacizumab
  • Brigatinib
  • Duarte, California
  • +4 more
Aug 17, 2022

Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Oslo, Norway
    Pfizer Norway
Apr 17, 2023

Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)

Completed
Has Results
  • Lymphoma, Large-Cell, Anaplastic
  • Carcinoma, Non-Small-Cell Lung
  • Brigatinib
  • (no location specified)
Jul 26, 2021

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Brigatinib
  • +4 more
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022

Anaplastic Large Cell Lymphoma, ALK-Positive Trial in Philadelphia (Brigatinib)

Withdrawn
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • Brigatinib
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jan 4, 2021

NSCLC Trial (Brigatinib)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Brigatinib
  • (no location specified)
Feb 18, 2021

Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Tumor, Advanced ALK+ or ROS1+Solid Tumors Trial in Worldwide (Midazolam,

Completed
  • Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
  • Paris, Ile-de-france, France
  • +13 more
May 19, 2021

ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

Active, not recruiting
Has Results
  • ALK-positive Advanced NSCLC
  • Brigatinib
  • Orange, California
  • +79 more
Nov 15, 2022

Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors

Withdrawn
  • Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma
  • +2 more
  • Brigatinib
  • Brigatinib AAF
  • (no location specified)
Mar 2, 2020

ALK+ Advanced NSCLC Trial in Worldwide (Brigatinib, Alectinib)

Recruiting
  • ALK+ Advanced NSCLC
  • Whittier, California
  • +113 more
Apr 1, 2022

Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer Trial in Italy (Erlotinib, Trastuzumab, Trastuzumab

Recruiting
  • Breast Cancer
  • +3 more
  • Ancona, Italy
  • +40 more
Jan 25, 2023

NSCLC, Lung Cancer, Advanced Malignancies Trial in Worldwide (Brigatinib, Crizotinib)

Completed
Has Results
  • Non-small Cell Lung Cancer
  • +3 more
  • Sedona, Arizona
  • +90 more
Jul 27, 2021

NSCLC, Lung Cancer, Advanced Malignancies Trial in La Jolla, Orange, Detroit (Brigatinib)

No longer available
  • Non-small Cell Lung Cancer
  • +3 more
  • Brigatinib
  • La Jolla, California
  • +2 more
Feb 5, 2018